ChemicalBook > CAS DataBase List > Roxadustat

Roxadustat

Product Name
Roxadustat
CAS No.
808118-40-3
Chemical Name
Roxadustat
Synonyms
FG-4592;Roxadustat (FG-4592);N-[(4-Hydroxy-1-Methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine;2-(4-hydroxy-1-Methyl-7-phenoxyisoquinoline-3-carboxaMido)acetic acid;ASP1517;FG-4592 (Roxadustat);IBT4A;CS-185;Rosasta;FibroGen
CBNumber
CB82538253
Molecular Formula
C19H16N2O5
Formula Weight
352.34
MOL File
808118-40-3.mol
More
Less

Roxadustat Property

Melting point:
199-215°C
Boiling point:
684.3±55.0 °C(Predicted)
Density 
1.389
storage temp. 
-20°C
solubility 
Soluble in DMSO (up to at least 25 mg/ml).
pka
2.46±0.10(Predicted)
form 
solid
color 
Off-white or white
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months.
InChI
InChI=1S/C19H16N2O5/c1-11-15-9-13(26-12-5-3-2-4-6-12)7-8-14(15)18(24)17(21-11)19(25)20-10-16(22)23/h2-9,24H,10H2,1H3,(H,20,25)(H,22,23)
InChIKey
YOZBGTLTNGAVFU-UHFFFAOYSA-N
SMILES
C(O)(=O)CNC(C1=C(O)C2=C(C(C)=N1)C=C(OC1=CC=CC=C1)C=C2)=O
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H332Harmful if inhaled

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P271Use only outdoors or in a well-ventilated area.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P304+P340IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

P312Call a POISON CENTER or doctor/physician if you feel unwell.

P321Specific treatment (see … on this label).

P330Rinse mouth.

P332+P313IF SKIN irritation occurs: Get medical advice/attention.

P362Take off contaminated clothing and wash before reuse.

P501Dispose of contents/container to..…

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
15294
Product name
FG-4592
Purity
≥98%
Packaging
5mg
Price
$32
Updated
2024/03/01
Cayman Chemical
Product number
15294
Product name
FG-4592
Purity
≥98%
Packaging
10mg
Price
$57
Updated
2024/03/01
Cayman Chemical
Product number
15294
Product name
FG-4592
Purity
≥98%
Packaging
25mg
Price
$86
Updated
2024/03/01
Cayman Chemical
Product number
15294
Product name
FG-4592
Purity
≥98%
Packaging
50mg
Price
$153
Updated
2024/03/01
TRC
Product number
H948180
Product name
N-[(4-Hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine
Packaging
50mg
Price
$195
Updated
2021/12/16
More
Less

Roxadustat Chemical Properties,Usage,Production

Description

Roxadustat is an orally administered, small molecule hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that is being developed by FibroGen, in collaboration with Astellas and AstraZeneca, for the treatment of anaemia in patients with dialysis-dependent chronic kidney disease (CKD), non-dialysis-dependent CKD and in patients with myelodysplastic syndromes.

Uses

Roxadustat is a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor used to increase white blood cell levels in blood and hematopoietic progenitor cells in bone marrow.

Definition

ChEBI: Roxadustat is an N-acylglycine resulting from the formal condensation of the amino group of glycine with the carboxy group of 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylic acid. It is an inhibitor of hypoxia inducible factor prolyl hydroxylase (HIF-PH). It has a role as an EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor and an EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor. It is a member of isoquinolines, an aromatic ether and a N-acylglycine.

Side effects

The most common side effects include hypertension, vascular access thrombosis (formation of blood clots in the blood vessels associated with dialysis), diarrhea, peripheral edema (swelling especially of the ankles and feet), hyperkalemia and nausea.

Synthesis

Preparation of roxadustat of formula 1 was described in a patent application WO2004108681, where the roxadustat is prepared in 11 steps from initial chemical compound 4-nitro-1,2-dicarbonitrile of formula 2. Reaction of dicarbonitrile of formula 2 with phenol and potash in the first step leads to preparation of corresponding phenoxy derivate of formula 3, 4-phenoxyphthalic acid of formula 4 is prepared by the following hydrolysis effect of potassium hydroxide in methanol, from which a solid-phase mixture with glycine is created for reaction in a melt with temperature of 210°C to 220°C, which provides corresponding phthalimide of formula 5. After that, phthalimide of formula 5 is esterified to corresponding methyl ester of formula 6. Then, expansion of the ring is performed by the effect of sodium butanolate to butyl-7-phenoxy-1,4-dihydroxy isoquinoline-3-carboxylate of formula 7. Hydroxyl group of derivative of formula 7 in a position 1 is then replaced by bromine using phosphorus oxybromide under the alkaline conditions resulting in creation of isoquinoline derivative of formula 8. Further the alkaline hydrolysis is carried out to provide an acid of formula 9. Then the lithiation is carried out, capture of lithium salt with methyl iodide, and in the second step, the hydroxyl group and carboxyl function are protected by benzyl group resulting in the derivative of formula 10. By the effect of potassium hydroxide the derivative of formula 10 is hydrolyzed to the carboxylic acid of formula 11, from which the derivative 12 is prepared under the conditions of glycine benzyl ester. The final step of synthesis of roxadustat of formula 1 is deprotection of benzyl groups by means of hydrogenation reaction (Diagram 1).

A Scalable Synthesis of Roxadustat (FG-4592)

target

HIF α prolyl hydroxylase

IC 50

IC50 = 591.4 nM (HIF-PH).IC50 values for inhibition of peak and late components of delayed rectifier calcium currents are 5.71 and 1.32 μM in pituitary tumor cells.

Metabolism

Roxadustat is metabolized by cytochrome P450 (CYP)2C8 and uridine diphosphate-glucuronosyltransferase (UGT)1A9. Roxadustat is primarily metabolized through 2 main metabolic pathways: hydroxylation/oxidation followed by sulfation, producing metabolites 4'-hydroxy roxadustat and 4'-O-sulfate conjugates of 4'-hydroxy roxadustat, together accounting for 20% of the radioactive dose. The O-glucuronidation produces metabolite 4-O-β-glucuronide of roxadustat, representing 28% of the dose. Minor metabolic routes included glucosidation producing 4-O-β-glucoside of roxadustat (8.1% of the dose), acyl glucuronidation producing acyl-1-O-β-glucuronide of roxadustat (0.6% of the dose), and demethylation producing N-descarboxymethyl roxadustat oxide and Ndescarboxymethyl roxadustat (together ~3.6% of the dose).

storage

Store at -20°C

Current market and forecast

Roxadustat is approved in EU member states, including the EEA countries, as well as in Japan, China, Chile and South Korea for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD). Several other licensing applications for roxadustat have been submitted by Astellas and AstraZeneca to regulatory authorities across the globe and are currently in review.
Astellas and FibroGen are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia of CKD in territories including Japan, Europe, Turkey, Russia and the Commonwealth of Independent States, the Middle East, and South Africa. FibroGen and AstraZeneca are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia of CKD in the U.S., China, other markets in the Americas, in Australia/New Zealand, and Southeast Asia.

Mode of action

Roxadustat is a novel, orally bioavailable, potent and reversible HIF-PH inhibitor (HIF-PHI) that transiently induces HIF stabilization and leads to a functional HIF transcriptional response that mimics the erythropoietic response associated with exposure of humans to intermittent hypoxia. roxadustat increases hemoglobin levels with a mechanism of action that is different from that of ESAs. Roxadustat activates the body’s natural protective response to reduced oxygen levels in the blood. This response involves the regulation of multiple, complementary processes that promote a coordinated erythropoietic response and increase the blood’s oxygen-carrying capacity.

Clinical claims and research

Roxadustat (FG-4592), an oral medication, is one of the medications currently undergoing Phase 3 studies. In their phase 2a study studying anemic CKD patients, the medication showed increases in erythropoietin and hemoglobin levels as well as a reduction in hepcidin concentrations with 0.7 to 2.0 mg/kg given 2 or 3 times per week compared to controls within 4 weeks of treatment with no adverse events observed. Roxadustat was then studied in hemodialysis and peritoneal dialysis patients and raised hemoglobin by 20 g/L in 7 weeks of treatment with 4.3 mg/kg weekly for 12 weeks. The current phase 3 studies will continue to evaluate Roxadustat compared to epoetin alpha(NCT02174731 ) and epoetin alpha or darbepoetin alpha (NCT02278341) in CKD patients on dialysis.

Roxadustat Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Roxadustat Suppliers

Toronto Research Chemicals
Tel
--
Fax
--
Email
info@trc-canada.com
Country
Canada
ProdList
6038
Advantage
71
More
Less

View Lastest Price from Roxadustat manufacturers

Zison Pharmaceutical (Shandong) Co., Ltd.
Product
Roxadustat 808118-40-3
Price
US $0.00-0.00/kg
Min. Order
1kg
Purity
>99% by HPLC
Supply Ability
10kg/month
Release date
2023-01-06
shandong perfect biotechnology co.ltd
Product
Roxadustat 808118-40-3
Price
US $0.00/g
Min. Order
1g
Purity
98% HPLC
Supply Ability
1kg
Release date
2023-08-02
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
Product
Roxadustat 808118-40-3
Price
US $0.00/g
Min. Order
1g
Purity
More Than 99%
Supply Ability
100kg/Month
Release date
2024-07-24

808118-40-3, RoxadustatRelated Search:


  • FG-4592
  • 2-(4-hydroxy-1-Methyl-7-phenoxyisoquinoline-3-carboxaMido)acetic acid
  • FG-4592; 2-(4-HYDROXY-1-METHYL-7-PHENOXYISOQUINOLINE-3-CARBOXAMIDO)ACETIC ACID
  • [[(4-Hydroxy-1-Methyl-7-phenoxyisoquinolin-3-yl)carbonyl]aMino]acetic Acid
  • N-[(4-Hydroxy-1-Methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine
  • FG-4592/FG4592
  • Glycine, N-[(4-hydroxy-1-Methyl-7-phenoxy-3-isoquinolinyl)carbonyl]-
  • FG-4592(ASP1517)
  • FibroGen
  • ROXADUSTAT;ASP1517;ASP-1517;FG 4592;FG4592
  • FG-4592 - Roxadustat | ASP 1517
  • FG-4592 (Roxadustat)
  • CS-185
  • 2-[(4-hydroxy-1-Methyl-7-phenoxyisoquinoline-3-carbonyl)aMino]acetic acid
  • [(4-Hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid(FG-4592)
  • Roxadustat (FG-4592)
  • ASP1517
  • N-[(4-Hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine [[(4-Hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl]amino]acetic acid
  • [[(4-Hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl]amino]acetic acid Roxadustat (FG-4592)
  • ROXADUSTAT
  • [(4-Hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
  • Glycine, N-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]- (Related Reference)
  • CM4309 TsOH
  • (4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)glycine
  • 2-(4-HYDROXY-1-METHYL-7-PHENOXYISOQUINOLINE-3-CARBOXAMIDO)ACETIC ACID(Roxadustat)
  • Roxadustat intermediates
  • Roxadustat Impurity ABCDEFGHJKL
  • FG-4592 USP/EP/BP
  • N-(4-Hydroxy-1-methyl-7-phenoxyisoquinolin-3-ylcarbonyl)glycine
  • Roxadustat D5Q: What is Roxadustat D5 Q: What is the CAS Number of Roxadustat D5
  • IBT4A
  • Rosasita
  • Rosasta
  • Roxadustat (Form A and L-Proline Co-Crystal)
  • Roxastat
  • 808118-40-3
  • Inhibitor
  • Aromatics
  • Heterocycles
  • Inhibitors
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • API
  • Intermediate
  • research chem
  • 808118-40-3